Item 7.01 Regulation FD Disclosure.

On August 5, 2021, Exicure, Inc. (the "Company") updated its corporate slide presentation for use in meetings with investors, analysts and others. The presentation is posted on the "Investors" portion of its website at https://investors.exicuretx.com/events-and-presentations/ and the slides are attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

The information in this Item 7.01 to this Current Report on Form 8-K, and including Exhibit 99.1 furnished herewith, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On August 5, 2021, the Company issued a press release announcing interim data from the Company's ongoing Phase 1b/2 clinical trial of cavrotolimod (AST-008), a copy of which is filed herewith as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



Exhibit No.               Description
99.1                        Corporate presentation dated August 5, 2021.
99.2                        Press release dated August 5, 2021.
                          Cover Page Interactive Data File (embedded within the Inline XBRL
104                       document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses